Grants for State governments - Federal

This funding opportunity supports research projects that develop innovative strategies to improve HIV prevention and treatment outcomes, particularly for marginalized populations, by addressing barriers and enhancing community engagement.

Recreational boating is a popular activity; there are approximately 11 million registered motorized recreational vessels in the United States. Of this total, an estimated 596,000 are at least 26 feet long. The Sportfishing and Boating Safety Act of 1998 (Public Law 105-178) established the Boating Infrastructure Grants (BIG) Program (16 U.S.C. 777g-1) to provide funding to the 50 States, the District of Columbia, the Commonwealths of Puerto Rico and the Northern Mariana Islands, and the territories of Guam, American Samoa, and the U.S. Virgin Islands (States) for the construction, renovation and maintenance of boating infrastructure facilities for transient recreational vessels at least 26 feet long that are operated, leased, rented, or chartered primarily for pleasure. The Act amended the Dingell-Johnson Sport Fish Restoration Act (16 U.S.C. 777). Subsequent reauthorizations of the Act allow expenditures from the Sport Fish Restoration and Boating Trust Fund and the continuation of the BIG Program. Boating infrastructure means the structures, equipment, accessories, and services that are necessary or desirable for a facility to accommodate eligible vessels. Transient vessels are those passing through or by a place, staying up to 15 days. Projects completed using BIG funds must provide public access, but may be publicly or privately owned. This package is the Notice of Funding Opportunity (NOFO) for Fiscal Year (FY) 2025 BIG Tier 2 applications.

This program is authorized by 34 U.S. C. 10441, 10446 10451, 10454. The Services* Training* Officers* Prosecutors (STOP) Violence Against Women Formula Grant Program (STOP Formula Grant Program) (Assistance Listing Number 16.588) supports communities, including American Indian tribes and Alaska Native villages, in their efforts to develop and strengthen effective responses to domestic violence, dating violence, sexual assault and stalking.

The Federal Transit Administration (FTA) announces the opportunity to apply for $51 million in competitive grants under the Fiscal Year (FY) 2024 Passenger Ferry Grant Program (PFG) (Federal Assistance Listing #20.532). Of that amount, $5 million is available only for low or zero-emission ferries or ferries using electric battery or fuel cell components and the infrastructure to support such ferries. As required by Federal public transportation law, funds will be awarded competitively to designated recipients or eligible direct recipients of Urbanized Area Formula funds to support capital projects to improve existing passenger ferry service, establish new ferry service, and repair and modernize ferry boats, terminals, and related facilities and equipment.

This grant provides a framework for the U.S. Army to manage and sustain training lands effectively, ensuring they meet the necessary standards for military readiness across various operations.

The Prevention Technology Transfer Centers (PTTC) program aims to maintain and enhance the PTTC Network, offering training and technical assistance to the substance misuse prevention field. The program targets professionals, pre-professionals, organizations, and communities involved in preventing substance misuse among children, youth, young adults, families, parents, and other adults. The goal is to improve the implementation and delivery of effective substance misuse prevention interventions through direct collaboration with SAMHSA and the PTTC Network. Eligible applicants include domestic public and private non-profit entities, with applications due by April 24, 2024. The anticipated total funding is $8,134,816, with an award ceiling of $739,529 per year for up to five years.

This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-22-NNN). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

This funding opportunity is designed to support the establishment of research centers that provide essential resources and infrastructure for advancing studies on rheumatic diseases, encouraging collaboration among researchers and institutions.

This funding opportunity supports U.S. educational institutions and organizations in developing group projects abroad that focus on modern foreign languages and area studies, particularly for less commonly taught languages, benefiting faculty, teachers, and students.

This funding opportunity provides financial support for research and evaluation projects aimed at improving policing practices, enhancing community relations, and ensuring evidence-based policymaking, targeting a wide range of eligible applicants including government entities, educational institutions, and nonprofit organizations.

This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

This funding opportunity provides financial support for projects that promote healthy relationships and marriage education for adults, with a focus on enhancing family stability and economic well-being.

This grant provides funding for innovative researchers to explore groundbreaking ideas that could transform the prevention and treatment of HIV/AIDS, particularly among individuals with substance use disorders.

This grant provides funding for multidisciplinary teams, including researchers, industry partners, and patient advocates, to develop innovative genetic therapies for rare hereditary diseases affecting millions of Americans, particularly children, by creating safe and effective one-time treatments.

This grant provides funding to state governments and their partners to develop innovative strategies that improve outcomes for youth in the juvenile justice system while reinvesting savings into effective prevention and intervention programs.

The "Blueprint MedTech Translator" grant aims to fund researchers to develop and test therapeutic and diagnostic devices for nervous or neuromuscular system disorders, with support for clinical trials, safety testing, design verification, and regulatory approvals, while also providing access to expert consultants and specialized research organizations.

The Statewide Family Network Program aims to enhance the capacity of statewide mental health family-controlled organizations. These organizations engage with family members and primary caregivers who are raising children, youth, and young adults with serious emotional disturbance (SED) and/or co-occurring disorders (COD). The program supports family-driven, trauma-informed, culturally relevant, holistic, and resiliency-oriented approaches. Eligible applicants include states and territories, political subdivisions of states, Indian tribes or tribal organizations, health facilities, and other public or private non-profit entities. Applications are due by April 8, 2024, with awards expected to start by September 30, 2024. The grant provides up to $120,000 per year for up to three years, with a total available funding of $1,116,777. Nine awards are anticipated. Cost sharing or matching is not required.

The "Announcement for Program Funding for NRCS Conservation Innovation Grants (CIG) for Federal fiscal year (FY) 2024 Vermont" is a funding opportunity offering up to $1,000,000 to stimulate the development and adoption of innovative conservation approaches and technologies in Vermont, with individual awards not exceeding $200,000, and applications are due by September 30, 2024.

The objective of this research proposal is to develop physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro in vivo correlations (IVIVCs) for two major types of long acting injectables (LAIs) such as crystalline suspensions and polymer-based implants by considering their distinct characteristics. The goal of the project is to develop a bottom-up mechanistic PBPK model for these two LAI categories by accounting for the influence of critical formulation attributes of each LAI drug product type to predict its in vivo release mechanism. The model formulation parameters and relevant physiology should be informed with suitable in vitro and in vivo experiments. A suitable preclinical animal model can be used to validate the PBPK model based IVIVCs for both LAI suspensions and polymer based implants. The use of PBPK modelling provides a unique opportunity to understand how the physicochemical properties of drug molecules/polymer, implant specific properties, critical formulation attributes, and physiology, among other things, influence the in vivo release mechanisms of LAI drug products and their disposition characteristics. Moreover, once developed, a mechanistic PBPK model can help to define the 'safe space' for critical formulation attributes relevant to the reference listed drug (RLD) product, explain sources of PK variability and extrapolate predictions to human subjects by leveraging animal model data and by accounting for species-specific physiological differences.

This funding opportunity supports research projects that investigate the relationship between HIV and aging, focusing on improving health outcomes for older adults living with HIV, particularly in diverse and underserved populations.